3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Gastrointestinal
2
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
178
Lung Neoplasms
56
NSCLC
11
Neoplasms
10
Neoplasm Metastasis
9
Brain Neoplasms
8
Carcinoma
7
Bronchial Neoplasms
5
Thoracic Neoplasms
4
Colorectal Neoplasms
4
Respiratory Tract Neoplasms
3
Respiratory Tract Diseases
3
Neoplasms by Site
3
Meningeal Carcinomatosis
3
Lung Diseases
3
Carcinoma, Squamous Cell
3
Breast Neoplasms
3
Adenocarcinoma of Lung
3
Adenocarcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Noonan Syndrome
2
Non Small Cell Lung Cancer Metastatic
2
Neoplasms, Nerve Tissue
2
Neoplasms by Histologic Type
2
Carcinoma, Bronchogenic
2
Triple Negative Breast Neoplasms
1
Interventions
pembrolizumab
34
Cisplatin
12
Nivolumab
10
atezolizumab
9
Docetaxel
9
Carboplatin
9
Paclitaxel
8
Cetuximab
8
Gemcitabine
7
Blood Specimen Collection
7
Radiotherapy
6
Fluorouracil
6
Drug Therapy
6
cemiplimab
5
Pemetrexed
5
Immune Checkpoint Inhibitors
5
fludarabine
4
Standard of Care
4
Cyclophosphamide
4
spartalizumab
3
epacadostat
3
Surveys and Questionnaires
3
Oncolytic Virotherapy
3
Nicotine
3
Magnetic Resonance Spectroscopy
3
Irinotecan
3
Interleukin-2
3
Filgrastim
3
Bupropion
3
Bortezomib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
osimertinib
×
Thoracic
×
Clear all
NCT05647122
2026-05-11
EGRET
AstraZeneca
Phase 1
Recruiting
403 enrolled